Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some claims about Sancuso being a granisetron transdermal patch, its intended use for CINV prevention, and core skin/sun precautions align with the provided labeling excerpts. However, multiple claims are not supported by the supplied label text (notably 72-hour coverage, 24-hour adhesion checks, and patent/generic-market assertions), reducing overall alignment.
Category Scores
Accurate Statements
A Sancuso patch is a transdermal patch containing granisetron.
Label shows Sancuso (granisetron transdermal system) and Dosage Forms/Strengths: patch releases granisetron.
Granisetron is a medication used to prevent nausea and vomiting caused by chemotherapy.
Indications and Usage: indicated for prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy.
Sancuso patch use may cause skin irritation or allergic reactions to the adhesive or other components of the patch.
Warnings/Precautions: Skin Reactions (application site reactions; if severe/generalized allergic rash occurs remove patch). Contraindication to hypersensitivity is also listed.
Unsupported Statements
According to the manufacturer's website, the Sancuso patch can provide effective antiemetic coverage for approximately 72 hours.
Not supported by the provided FDA label excerpts. Label indicates patch can be worn up to 7 days and is applied 24–48 hours before chemo with removal 24 hours after completion; no “approximately 72 hours” coverage claim is present in the excerpted label.
The manufacturer recommends checking for proper patch adhesion every 24 hours and adjusting as necessary to ensure effective drug delivery.
Not supported by the provided FDA label excerpts. Label provided includes application site selection and general application/removal timing, but no instruction to check adhesion every 24 hours or adjust for delivery effectiveness.
Patients using Sancuso patches should be advised on proper adhesive application and wearing technique.
Not supported as a specific “should be advised” wearing-technique/adhesive guidance in the provided excerpts. The label excerpt includes how/where to apply (clean, dry intact healthy skin; upper outer arm; do not place on red/irritated/damaged; apply after pouch opened; do not cut), but it does not state “wearing technique” or “adhesive application advice” as written.
The patent for granisetron, the active ingredient in Sancuso, expired in some regions, allowing generic versions of granisetron to enter the market.
Not addressed in the provided FDA label excerpts.
The Sancuso brand name is still protected.
Not addressed in the provided FDA label excerpts.
Generic transdermal patches may not be identical in terms of quality or efficacy.
Not addressed in the provided FDA label excerpts.
Contradictions
Important Omissions
Timing and duration details from the label (apply 24 hours to 48 hours before chemotherapy; remove a minimum of 24 hours after completion; can be worn up to 7 days; do not cut patch). These are not explicitly covered by the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported/label-inconsistent operational claims (e.g., 72-hour coverage and 24-hour adhesion-check/adjustment instructions) could mislead patients/caregivers about correct patch use, while other safety-related statements (skin reactions, sunlight-related precautions) are not fully evaluated here due to excerpt limitations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not supported by the provided FDA label excerpts, including specific “72-hour” efficacy coverage, “check adhesion every 24 hours/adjust as necessary,” and all patent/generic-market statements.
Suggested Improvement
Remove or rephrase unsupported claims. If retention of use-instructions is needed, align to label text (clean/dry intact skin on upper outer arm; do not place on irritated/damaged skin; apply after pouch opened; do not cut; apply 24–48 hours before chemo; remove at least 24 hours after completion; can wear up to 7 days; cover site to prevent sunlight exposure during wear and 10 days after removal).